Skip to main content
  • Home
  • Hypertrophic Cardiomyopathy: Application of Emerging Data and Genetic Testing in Clinical Practice

Hypertrophic Cardiomyopathy: Application of Emerging Data and Genetic Testing in Clinical Practice

Topic:
  • Heart Failure

Available Credit:

  • 0.75 AMA PRA Credit

Course Published On:

Course Expiry Date:

Release / Expiration Date

February 17th, 2022 – February 17th, 2023

Method of Participation

This activity will take approximately 45 minutes to complete. To receive credit, participants are required to view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. There is no fee to participate in the activity or for the generation of the certificate.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Academy for Continued Healthcare Learning (ACHL) and Radcliffe Medical Education. ACHL is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Nurse practitioners may participate in this educational activity and earn a certificate of completing as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.

Commercial Support

This activity is supported by an educational grant from Bristol Myers Squibb.

Faculty Disclosures

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity. 

 

The following financial relationships have been provided:

 

Research Support: MyoKardia/BMS
Consulting: Cytokinetics, MyoKardia/BMS, Novartis, Tenaya 

 

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: The use of unlabelled drugs (mavacamten and aficamten) will be discussed

Staff and Reviewer Disclosures

ACHL and Radcliffe Medical Education staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Terms & Conditions

DISCLAIMER

 

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

 

This CME activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Target Audience

  • This activity is intended for cardiologists, heart failure specialists and allied healthcare professionals.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Recall the efficacy and safety of existing HCM treatments
  • Summarise results from ongoing trials with experimental treatments
  • Stratify individuals with HCM signs and symptoms for subsequent investigation and/or genetic screening
Register now Log in

Speaker

Carolyn Ho

Brigham and Women’s Hospital, USA

Dr Carolyn Ho is the medical director of the Cardiovascular Genetics Center at Brigham and Women’s Hospital. Dr Ho is also an associate professor of medicine at Harvard Medical School.

View full profile

AVAILABLE CREDIT

0.75 AMA PRA Category 1 Credit™

Related Courses

SGLT-2 Inhibitors - Another Piece of the Puzzle in Heart Failure
  • 1 EBAC

Learning objectives

  • Recall the results of key trials in HFmrEF in different patients' sub-groups
  • Describe how SGLT-2 inhibitors can be used across the range of LVEF
  • Apply emerging diagnostic approaches for HFpEF and HFmrEF
  • Implement best-practice strategies across the range of LVEF
See more
Making Gains in HFpEF: An Appraisal of Where We Are Now

Learning objectives

  • Identify HFpEF patients who may benefit from being initiated on an SGLT-2 inhibitor
  • Recall current inertia rates amongst prescribers who manage heart failure
  • Adopt effective treatment strategies for HFpEF patients early in the disease course
  • Recall current guideline directed medical therapy options in HFpEF
  • Review clinical, real world and quality of life evidence for the use of SGLT-2 inhibitors in HFpEF
See more
Heart Failure Management in a Changing Paradigm
  • 1 EBAC

Learning objectives

  • Recall the utility of EF in heart failure treatment, patient selection and treatment response
  • Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy
  • InIncorporate quality of life measures for assessing therapeutic efficacy in HF
  • Recall outcomes from heart failure trials from recent congress and publications and their impact on practice
See more
The 2022 ACC Heart Failure Guidelines: What Do They Mean for Your Practice?

Learning objectives

  • Summarise the main updates to the 2022 ACC heart failure (HF) guidelines
  • Compare updates from the ACC with the 2021 ESC HF guidelines
  • Recall guideline recommendations for the initiation of foundational therapy for heart failure
  • Adopt foundational GMDT early in the disease course
  • Postulate how ejection fraction will be used in future trials and in future guidelines
  • Review existing and forthcoming trial evidence on SGLT-2 inhibitors in HFpEF
See more
HFO 2022 - Session 3.3: Live Case & Discussion
  • 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

Learning objectives

  • Select foundational and advanced management strategies in complex patients
  • Discuss the validity of using ejection fraction to determine optimal treatment strategies
  • Assess the likely impact of health technology on future practice
  • Identify the underlying causes of heart failure
  • Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
  • Assess the impact of the multidisciplinary team on heart failure outcomes
  • Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
See more
HFO 2022 - Session 3.1 & 3.2: Quality of Life and Multi-disciplinary Care in HF
  • 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

Learning objectives

  • Select foundational and advanced management strategies in complex patients
  • Discuss the validity of using ejection fraction to determine optimal treatment strategies
  • Assess the likely impact of health technology on future practice
  • Identify the underlying causes of heart failure
  • Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
  • Assess the impact of the multidisciplinary team on heart failure outcomes
  • Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
See more
HFO 2022 - Session 2.5 Practical Theory & Hot Topics: Advanced HF Care
  • 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

Learning objectives

  • Select foundational and advanced management strategies in complex patients
  • Discuss the validity of using ejection fraction to determine optimal treatment strategies
  • Assess the likely impact of health technology on future practice
  • Identify the underlying causes of heart failure
  • Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
  • Assess the impact of the multidisciplinary team on heart failure outcomes
  • Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
See more
HFO 2022 - Session 2.3 Practical Theory & Hot Topics: HF Aetiology
  • 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

Learning objectives

  • Select foundational and advanced management strategies in complex patients
  • Discuss the validity of using ejection fraction to determine optimal treatment strategies
  • Assess the likely impact of health technology on future practice
  • Identify the underlying causes of heart failure
  • Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
  • Assess the impact of the multidisciplinary team on heart failure outcomes
  • Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
See more
HFO 2022 - Session 2.2 Live Case and Discussion
  • 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

Learning objectives

  • Select foundational and advanced management strategies in complex patients
  • Discuss the validity of using ejection fraction to determine optimal treatment strategies
  • Assess the likely impact of health technology on future practice
  • Identify the underlying causes of heart failure
  • Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
  • Assess the impact of the multidisciplinary team on heart failure outcomes
  • Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
See more
HFO 2022 - Session 1.4 Practical Theory & Hot Topics: Transitioning Care and Monitoring Technology
  • 1.00 European Board for Accreditation of Continuing Education for Health Professionals (EBAC)

Learning objectives

  • Select foundational and advanced management strategies in complex patients
  • Discuss the validity of using ejection fraction to determine optimal treatment strategies
  • Assess the likely impact of health technology on future practice
  • Identify the underlying causes of heart failure
  • Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
  • Assess the impact of the multidisciplinary team on heart failure outcomes
  • Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
See more